Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept plus methotrexate vs methotrexate monotherapy in early rheumatoid arthritis (Japan, Phase 3B)
jRCT2080223027Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of abatacept in rheumatoid arthritis (RA) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Clinical remission rate. Started Nov 2015; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080223027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223027.